# SCIENTIFIC **Reports**

Received: 16 June 2017 Accepted: 8 September 2017 Published online: 05 December 2017

## **OPEN** Altered expression of metabolites and proteins in wild and caged fish exposed to wastewater effluents in situ

D.B.D. Simmons<sup>1</sup>, J. Miller<sup>1</sup>, S. Clarence<sup>1</sup>, E.S. McCallum<sup>2</sup>, S. Balshine<sup>2</sup>, B. Chandramouli<sup>3</sup>, J. Cosgrove<sup>3</sup> & J.P.Sherry<sup>1</sup>

Population growth has led to increased global discharges of wastewater. Contaminants that are not fully removed during wastewater treatment, such as pharmaceuticals and personal care products (PPCPs), may negatively affect aquatic ecosystems. PPCPs can bioaccumulate causing adverse health effects and behavioural changes in exposed fish. To assess the impact of PPCPs on wild fish, and to assess whether caged fish could be used as a surrogate for resident wild fish in future monitoring, we caged goldfish in a marsh affected by discharges of wastewater effluents (Cootes Paradise, Lake Ontario, Canada). We collected plasma from resident wild goldfish, and from goldfish that we caged in the marsh for three weeks. We analyzed the plasma proteome and metabolome of both wild and caged fish. We also compared proteomic and metabolic responses in caged and wild fish from the marsh to fish caged at a reference site (Jordan Harbour Conservation Area). We identified significant changes in expression of over 250 molecules that were related to liver necrosis, accumulation and synthesis of lipids, synthesis of cyclic AMP, and the quantity of intracellular calcium in fish from the wastewater affected marsh. Our results suggest that PPCPs could be affecting the health of wild fish populations.

There is growing societal concern about the environmental fate and inadvertent effects of pharmaceuticals and personal care products (PPCPs). After use or disposal, PPCPs often end-up in wastewater, which then undergoes a multi-step treatment process at municipal wastewater treatment plants (WWTPs) to remove solids, bacteria, and nutrients. WWTPs, however, do not remove all chemical contaminants. In particular, PPCPs have been detected in wastewater effluents and recipient surface waters around the globe<sup>1-4</sup>. Pharmaceuticals are specifically designed to elicit a biological effect in humans. There is growing evidence that these drugs can also have biological effects in non-target organisms that might live in or around recipient waters<sup>5-9</sup>. For example, many PPCPs can also cause endocrine disruption in aquatic organisms<sup>9,10</sup>.

Cootes Paradise Marsh (CPM) is a large and ecologically important wetland on the west side of Hamilton Harbour (ON, Canada). CPM is included in the Hamilton Harbour Area of Concern, which is one of seven Areas of Concern on Lake Ontario identified in the Great Lakes Water Quality Agreement<sup>11</sup>. CPM has suffered considerable habitat destruction and subsequent loss of biodiversity, caused primarily by water pollution from municipal wastewaters (treated effluents and combined sewer overflows), the extensive proliferation of invasive common carp (Cyprinus carpio)<sup>12,13</sup>, and more recently an explosion of goldfish (Carassius auratus). Both carp and goldfish can tolerate a wide range of environmental conditions, including the ability to handle low levels of dissolved oxygen and higher levels of contamination compared to other fish species<sup>14-16</sup>. As part of remediation efforts in CPM, a carp exclusion program was established (and more recently a goldfish removal effort was attempted)<sup>17</sup>, and upgrades were added to the Dundas WWTP. In a previous study of fish captured from CPM, the occurrence of gonadal intersex and elevated plasma vitellogenin was observed in native male white perch (Morone americana) captured from CPM. Those reproductive system effects were linked to the potential presence of estrogenic compounds in the marsh water<sup>18</sup>.

<sup>1</sup>Aquatic Contaminants Research Division, Water Science and Technology Directorate, Environment and Climate Change Canada, Burlington, ON, Canada. <sup>2</sup>Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton, ON, Canada. <sup>3</sup>Metabolomics Services, SGS AXYS, Sidney, BC, Canada. Correspondence and requests for materials should be addressed to J.S. (email: jim.sherry@canada.ca)



**Figure 1.** Map of caging and wild fish capture sites in Cootes Paradise Marsh (CPM) and the reference site, Jordan Habour (JH). The base map is from the Atlas of Canada (with permission of Natural Resources Canada).

As part of a larger investigation of the effects of PPCPs in CPM on wild fish<sup>19,20</sup>, the goal of the present study was to investigate if PPCPs present in the treated effluent entering CPM have an impact on wild fish, we collected and tested plasma from both caged fish and wild fish living in CPM for signals of endocrine disruption and molecular level effects. An advantage of blood plasma as a monitoring tool is that it contains molecules from every organ and tissue within the organism as it circulates the entire body. We used responses of the plasma metabolome and proteome to characterize molecular effects. Assuming that a complex mixture of PPCPs would be present in CPM, and that such mixtures could have effects on many different biological functions, we anticipated that our use of multiple 'omics tools to measure responses in plasma would reveal global molecular responses from the entire organism. We complimented our 'omics approach with measures of fish survival, plasma vitellogenin, and body morphometrics. We also examined effects in wild goldfish because they are so were abundant in CPM while populations of native fish species are either in decline or in recovery. To link effects observed in wild goldfish specifically to WWTP effluent exposure we caged naïve goldfish as a surrogate for wild fish along a gradient of exposure starting from near the outfall of the Dundas WWTP, and then at two sites further downstream of the outfall and further into CPM (Fig. 1). We also caged goldfish at Jordan Harbour (JH), a conservation area on Lake Ontario and distant from WWTP effluent outfall, as our reference for comparison of responses in both wild-captured and caged goldfish, as we failed to capture wild goldfish in the conservation area (Fig. 1).

			CPM1			CPM2			СРМЗ					
Symbol	Name	NCBI Accession Number	Log2(FC)			p-value	Log2(FC)			p-value	Log2(FC)			p-value
Aftph	Aftiphilin	CDQ90298.1	1.3398		2	0.0840	0.9438			0.1663	0.9616			0.3223
Ankrd12	Ankyrin repeat domain-containing protein 12	XP_005751611	-0.3306			0.4157	-1.0392		2	0.0925	-1.0392		2	0.0925
Ash1l	Histone-lysine N-methyltransferase	XP_003966329	-2.1063		2	0.0611	-1.0906		2	0.0850	-0.4282			0.2584
Atad2b	ATPase family AAA domain-containing protein 2B	AAW82445.1	-0.0733			0.2752	-0.0796			0.2613	-0.1773			0.0102
Brd1	Bromodomain-containing protein 1	XP_698063.5	2.6465		2	0.0011								
Btd	Biotinidase	XP_004073869	-2.3530		\$	0.0078	-0.0672			0.7855				
C3	Complement C3	BAA36618.1	0.3364		2	0.0249	-0.0230			0.8971	-0.2418			0.2116
Chmp6	Charged multivesicular body protein 6	ACO09124.1	1.4989		2	0.0791	1.2470			0.2029	1.1647			0.1555
Cracr2a	EF-hand calcium-binding domain-containing protein 4B	XP_005805973	0.0152			0.9725	0.7374		2	0.0141	-0.6697			0.3628
Cyp51a1	Lanosterol 14-alpha demethylase	CDQ67700.1	-1.6909			0.0781	-0.4367			0.3302	-1.6909			0.0781
Daam1	Disheveled-associated activator of morphogenesis 1	XP_004541887	-0.0525			0.8470	0.1344			0.5305	-0.5285		2	0.0950
Dab2ip	Disabled homolog 2-interacting protein	XP_003976523	-1.5858		2	0.0920	-1.5858		2	0.0920	-0.3229			0.4717
Epdr1	Mammalian ependymin-related protein 1	AAB40068.1	-0.9388		2	0.0140	0.4635		2	0.0022	-0.0784			0.7044
Epm2a	Laforin, isoform 9	CDQ80564.1	2.0074			0.3223	2.3361		2	0.0791	1.3535			0.3223
Fetub	Fetuin-B	ABA33614.1	0.0907			0.2643	-0.1724		2	0.0376	-0.5017			0.0000
Fgg	Fibrinogen gamma chain	ABD83891.1	0.2229			0.2677	0.3162		2	0.0100	-0.2098			0.2499
Fn1	Fibronectin	AAU14809.1	1.6460		2	0.0111	0.2799			0.6182	-0.5854			0.3223
Hbb	Hemoglobin subunit beta	P02140.1	3.4162		2	0.0000	3.2752		2	0.0000	3.3314		2	0.0000
Hbe1	Hemoglobin subunit epsilon	0606173B	-3.3963		\$	0.0000	-3.3963		\$	0.0000	-3.3963			0.0000
Нрх	Hemopexin	BAD98538.1	-0.3167		2	0.0000	-0.4065		2	0.0000	-0.2872			0.0000
Ifi44	Interferon-induced protein 44	AAP20189.1	1.6710		\$	0.0469	1.7527		\$	0.0491	1.3617			0.1302
lglc6	Ig lambda-6 chain C region	BAB90987.1	-0.3079		2	0.0872	-0.3931		\$	0.0661	0.0473			0.6738
ll 10rb	Interleukin-10 receptor subunit beta	ABJ97307.1	0.7637			0.3223	2.6225		\$	0.0012				
Myo5c	Unconventional myosin-Vc	CAG05565.1	0.3535			0.2569	-0.0415			0.9145	-1.9834			0.0640
Nphs1	Nephrin	CAG12048.1	0.3930		\$	0.0262	0.1591			0.4757	0.1789			0.3015
Or52k1	Olfactory receptor 52K1	CAG09001.1	0.1047			0.3384	0.2079		\$	0.0772	-0.2994			0.0182
Psme4	Proteasome activator complex subunit 4	XP_004077490	0.0660			0.4604	0.0653			0.3722	0.1919			0.0080
Serpina1	Alpha-1-antitrypsin	AAA73954.1	-0.2322		\$	0.0674	-0.3847		\$	0.0304	-0.3144		\$	0.0228
Serpina5	Plasma serine protease inhibitor	AG058874.1	-0.2489			0.1900	0.6049		\$	0.0000	-0.0794			0.6424
Smyd2	N-lysine methyltransferase SMYD2	DAA01312.1	2.0448		\$	0.0955					1.1213			0.3223
Snrnp25	U11/U12 small nuclear ribonucleoprotein 25 kDa protein	XP_003442116	-1.0079		\$	0.0005	-0.9440			0.0006	-0.5276			0.0156
Sptbn1	Spectrin beta chain, non-erythrocytic 1	CAG13137.1	1.9156		2	0.0989	1.8807			0.3223				
Taf2	Transcription initiation factor TFIID subunit 2	CAF95588.1	-0.4629			0.3282	-1.8733		\$	0.0928	-1.8733			0.0928
Tf	Serotransferrin	P80426.1	0.4175		2	0.0050	0.6721		\$	0.0012	0.3570			0.0075
Usp39	U4/U6.U5 tri-snRNP-associated protein 2	XP_003975010	1.2085		\$	0.0276	0.9418		\$	0.0611	0.6728		2	0.0984
Znf500	Zinc finger protein 500	CAG00059.1	-0.5077			0.0714	-0.5119		2	0.0694	-0.7805			0.0193

**Figure 2.** List of proteins with symbol, name, function (if known), fold change ( $log_2(FC)$ ), and p-value that were differentially expressed in goldfish plasma for each caging location in CPM compared to expression at the reference site, JH. Red bars indicate increased expression while green bars indicate decreased expression. The size of the bar represents the magnitude of the difference.

.....

#### Results

**Survival.** There were no acutely lethal effects observed in our caged goldfish – 199 out of 200 fish survived the three-week deployment. The only fish mortality was in a cage at JH and that death was not likely related to exposure or to the caging environment.

**Biometrics.** There was no effect of site on the investment in reproductive organs (as measured by the GSI, see methods below) or body condition for the male caged goldfish (Supplementary Table S1).

**Vitellogenin.** Vitellogenin (an egg yolk precursor protein, used as a biomarker of environmental estrogen exposure) was detected in the plasma of only one goldfish caged at CPM1 (86 ng/ml) and was also detected in one goldfish caged at JH (27.6 ng/ml).

Proteins. We employed an untargeted shotgun proteomics approach to identify plasma proteins. Among the plasma proteins we detected in caged male goldfish, the expression of 36 proteins were significantly different in at least one exposure location in CPM compared to the reference site JH (Fig. 2). Of those, 12 were increased and 10 were decreased in goldfish caged closest to the WWTP outfall at CPM1, 11 were increased and 11 were decreased in goldfish caged further away at CPM2, and 4 were increased and 13 were decreased in goldfish caged the farthest from the WWTP outfall at CPM3. In the plasma of wild goldfish captured from CPM, the expression of 43 proteins was significantly increased and 18 proteins were significantly decreased compared to goldfish caged at the reference site JH (Fig. 3). Upon visual inspection of the fold changes values, the expression patterns of 26 proteins demonstrated a trend that could be related to distance along the plume from the WWTP outfall (either CPM1  $\ge$  CPM2  $\ge$  CPM3 or CPM3  $\ge$  CPM2  $\ge$  CPM1). Protein search scores, percent protein coverage, and accession numbers are included in Supplementary Table S2; further details for single peptide IDs are included in Supplementary Table S3. On average, the log2 fold change for plasma proteins in wild goldfish was 48x greater than for the caged goldfish ( $48 \pm 19$ ; mean ( $|log2FC_{wild}|/|log2FC_{caged}|) \pm 95\%$  CI). Of the 36 proteins in caged goldfish at CPM that were identified as being significantly different compared to the goldfish caged at the reference JH, 14 were also identified as significantly different in the wild goldfish from CPM. Among those 14 proteins, 6 proteins from fish caged at CPM1, 5 proteins from fish caged at CPM2, and 8 proteins from fish caged at CPM3 were differentially expressed in the same direction as in the wild goldfish plasma.

**Metabolites.** We used a targeted method to quantify plasma metabolites. Of the 218 targets, we detected 194 metabolites in the plasma samples from the caged goldfish (Fig. 4). Of those, the concentrations of 48 increased and 39 decreased in goldfish caged closest to the WWTP outfall at CPM1 compared to fish at the reference site JH. In goldfish caged further away at CPM2, 22 metabolites increased and 74 decreased. Finally, 44 metabolites increased and 54 decreased in goldfish farthest from the WWTP outfall at CPM3. For the wild goldfish from CPM, 27 of the 218 metabolite targets were not detected in the plasma of any fish. Of those metabolites that were detected, the concentrations of 77 were decreased and 57 were increased compared to the plasma of fish caged at JH (Fig. 5). Upon visual inspection of the fold changes values, 58 metabolites demonstrated

Symbol	Name	NCBI Accession Number	Log2(FC)		p-value
432910672	Uncharacterized protein LOC1101162953 isoform X1	XP_004078468.1	-8.4889		0.025382
A2m	Alpha-2-macroglobulin	BAA85038.1	5.707		0.00012494
Akap2	A-kinase anchor protein 2	M4A2Z9	7.2334		0.050693
Akna	AT-hook-containing transcription factor	W5KXY7	7.5978		0.067225
Apoa1	Apolipoprotein A-I	ABY47600.1	1.8263		7.55E-08
Ash1l	Histone-lysine N-methyltransferase ASH1L	XP 003966329	5.5217		0.00027574
Atad2b	ATPase family AAA domain-containing protein 2B	AAW82445.1	-15.999		9.27E-11
Calcr	Calcitonin receptor	M3ZEN5	5.1776		0.00016429
Ckm	Creatine kinase M-type	XP 003976526.1	10.781		0.00086577
Cldn4	Claudin-4	XP 004076228	7.7221		0.04852
Dennd3	DENN domain-containing protein 3	CAF99362.1	4,7247		0.055787
Dpysl2	Dihydropyrimidinase-related protein 2	A0A087XDY8	5,533		0.054144
Epdr1	Mammalian ependymin-related protein 1	AAB40068.1	-10.236		0.00943
Fetub	Fetuin-B	ABA33614.1	-4.1762		4.04F-08
Fgb	Fibringen beta chain	AAH66629.1	-1.4187	Ē	0.08242
Fgg	Fibringen gamma chain	ABD83891 1	-7 7991		0.0055579
Gfm2	Rihosome-releasing factor 2 mitochondrial	W5KBN7	7 9035		0.00038671
Gga3	ADP-ribosvlation factor-binding protein GGA3	XP 003972033	10.03		0.0060917
Hba1	Hermanna brunni anna processo Hermanna processo	06061734	-12 814		3 27E-05
Hba1	Hemoglobin subunit aprila	06061738	0 78024		0.026579
Hba	Hamaglabin suburit asta	10183614	12 020		1.055.07
HDZ	Hemopolini soluti zeta	1910301A	14 627		0.255.14
1642		DAD50350.1	-14.037		9.550-14
11(45	intranagenar transport protein 45 nomolog	N44L52	5.1400		0.009212
igk IslaC		BAB91007.1	9.1081		2.035.00
Igico	ig lambda-6 chain C region	BAB90987.1	-10.099		2.03E-06
ікокар	Elongator complex protein 1	XP_005808681	-8.936		0.074634
Irt2bp2	Interferon regulatory factor 2-binding protein 2	H3CB65	9.0599		0.033646
Kiaa1549	UPF000b protein kIAA1549	XP_004070245	-5.5009		0.086949
Kihi20	Kelch-like protein 20	I3KSB1	6.6534		0.00087304
Leo1	RNA polymerase-associated protein LEO1	H2LD28	11.074		0.0037976
Loc100996750	keratin-associated protein 4-7	AGO58874.1	5.9157		0.0059024
Lrp4	Low-density lipoprotein receptor-related protein 4	CAF99960.1	3.7663		0.020984
Mcl1	Induced myeloid leukemia cell differentiation protein Mcl-1	ABD85567.1	5.4808		0.018276
Msto1	Protein misato homolog 1	G3NSD1	6.3608		0.041254
Myof	Myoferlin	NP_957169.2	6.7564		0.028795
Nefh	Neurofilament heavy polypeptide	XP_005168545.1	9.0142		0.0014957
Or52k1	Olfactory receptor 52K1	CAG09001.1	-9.0492		7.28E-07
Pcp4	Purkinje cell protein 4	XP_005744222.1	6.9566		0.043923
Pdzd8	PDZ domain-containing protein 8	A0A087X906	4.4932		0.06951
Pkir	Pyruvate kinase PKLR	XP_004077971.1	-9.9459		0.076123
Pkm	Pyruvate kinase PKM	ABJ98638.1	9.9667		0.0029657
Polr3b	DNA-directed RNA polymerase III subunit RPC2	G3PDG5	3.4313		0.034518
Prss12	Neurotrypsin	CDQ89122.1	5.188		0.016095
Psme4	Proteasome activator complex subunit 4	XP_004077490	-10.741		3.71E-07
Rarres3	Retinoic acid receptor responder protein 3	XP_005812815.1	-6.3808		0.034616
Rbp3	Retinol-binding protein 3	ABC39738.1	-4.0073		0.070887
Rgl1	Ral guanine nucleotide dissociation stimulator-like 1	H2U1L5	8.5226		0.038021
Ryr2	Ryanodine receptor 2	CAG03532.1	-10.364		0.00014314
Serpina1	Alpha-1-antitrypsin	AAA73954.1	0.61825		0.061157
Serpina5	Plasma serine protease inhibitor	AGO58874.1	-9.0081		0.0039315
Sesn1	Sestrin-1	W5U6T2	7.9448		0.061628
SIc45a4	Solute carrier family 45 member 4	CAF99362.1	9.7671		0.073334
Smarcad1	SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A containing DFAD/H box 1	NP 001018610.2	4.7481		0.094413
Smc4	Structural maintenance of chromosomes protein 4	XP 005742218.1	5,7093		0.043359
Smchd1	Structural maintenance of chromosomes flexible hinge domain-containing protein 1	XP 005922666	2,2562		0,0806
St8sia5	Alpha-2.8-sialvitransferase 8F	AAI53663.1	9.209		0.00012903
Tf	Servirasferin	P80426 1	4 3661		2 95E-10
Trin12	F3 ubiquitin-protein ligase TRIP12	XP_005159283	7 6062		0.0067699
111/2	Seria / Hrannia - Arna III/2	XP_002664661.3	6 5126		0.047277
Znf500	Zinc finger protein 500	CAG00059 1	1 8306		0.071302
2111500 7n4	Zinciniger protein 300	XP 005012025 1	6.0053		0.071302
2µ4	Zona penduda sperni-binding protein 4	AP_003912055.1	0.0003		0.092441

**Figure 3.** List of proteins with symbol, name, function (if known), fold change ( $\log_2(FC)$ ), and p-value that were differentially expressed in wild male goldfish plasma from CPM compared to expression in goldfish caged at the reference site, JH. Red bars indicate increased expression while green bars indicate decreased expression. The size of the bar represents the magnitude of the difference.

.....

expression patterns that could be related to distance from the WWTP outfall (either CPM1  $\geq$  CPM2  $\geq$  CPM3 or CPM  $\geq$  CPM1). On average, the log2 fold change for plasma metabolites in wild goldfish was 31x greater than for the caged goldfish (31  $\pm$  10; mean ( $|log2FC_{wild}|/|log2FC_{caged}|$ )  $\pm$  95% CI). Of the 159 metabolites in caged goldfish at CPM that were identified as being significantly different compared to the goldfish caged at the reference JH, 109 were also identified as significantly different in the wild goldfish from CPM. Among those 109 metabolites, 58 metabolites from fish caged at CPM1, 65 metabolites from fish caged at CPM2, and 51 metabolites from fish caged at CPM3 were differentially expressed in the same direction as in the wild goldfish plasma.

**Biological functions.** The Ingenuity Pathways Analysis (IPA core analysis) identified 47 biological functions that were considered significantly activated or inhibited, based upon expression of both plasma proteins and metabolites of caged male goldfish and wild male goldfish from CPM compared to fish from the reference site at JH (Table 1). In fish caged closest to the outflow at CPM1, liver necrosis functions, and metal ion transport were activated, and synthesis of cyclic AMP was inhibited. Uptake of amino acids was activated, while growth of organism and entry into S-phase cell division were inhibited in fish caged further from the WWTP outfall at CPM2. At CPM3, furthest from the WWTP outfall, accumulation of lipids and glyceride were activated, and growth of organism, synthesis of cyclic AMP, and quantity of steroid were inhibited. In the wild male goldfish from CPM, cell survival, concentration of glutathione, and contractility of heart were activated, whereas apoptosis was inhibited. Additionally, IPA analysis identified 6 similar functions that were affected in the wild and caged goldfish (uptake of amino acids, uptake of L-amino acid, uptake of L-alanine, quantity of metal, quantity of Ca<sup>2+</sup>, and accumulation of lipids), but their predicted activation states were in opposite directions (Table 1).



**Figure 4.** List of metabolites with class of molecule, common name, human metabolome database identifier (HMDB ID), fold change ( $\log_2(FC)$ ), and p-value that were differentially expressed in goldfish plasma for each caging location in CPM compared to expression in plasma collected from goldfish at the reference site, JH. Red bars indicate increased expression while green bars indicate decreased expression. The size of the bar represents the magnitude of the difference.

### Discussion

We used an 'omics approach to understand the molecular effects of exposure to wastewater effluent in goldfish caged for three weeks compared to wild fish that would have been chronically exposed throughout their lifetime. For proteins and metabolites together, there was close to 75% agreement in the direction of fold change expression

Class	Name	HMDBID	Log2(FC)	p-volue
	3-Methylglutarylcarnitine	HMDB00552	9.6571	0.0198
	Acetylcarnitine	HMDB00201	1.4036	0.0012
	Carnitine	METPA0048	1.1055	0.00022
	Decanoylcarnitine	HMD800651	-0.5394	0.0597
	Dodecanoylcarnitine	HMD802250	11.7470	0.0232
	Glutandramitine	HMD806464 HMD813130	3.8415	0.0584
Se la	Hexanoylcarnitine	HMD800705	3.1266	0.0002
iĝi.	Hydroxybutyrylcarnitine	HMD613127	4.2850	0.0000
Car	Hydroxyvalerylcarnitine	HMD613132	10.9240	0.0005
	L-Palmitoylcarnitine Octanoulcarnitine	HMD800222	12.8840	0.0018
	Propionylcarnitine	HMD800824	2.7233	0.0000
	Stearoylcarnitine	HMD600848	10.9770	0.0556
	Tetradecanoylcarnitine	HMD805066	12.3380	0.0105
	Tiglylcarnitine	HMDB02366	12.3900	0.0000
	trans-Hexadec-2-encyl carnitine	HMD806317	11.6810	0.0106
	Alaoine	HMD613128 METPA0179	1.5281	0.0000
	alpha-Aminoadipic acid	HMD800510	1.4979	0.0032
	Arginine	HMDB00517	0.3998	0.0280
	Asparagine	HMDB00168	-0.3639	0.0326
	Asymmetric dimethylarginine Citrulline	HMDB01539 HMDB00904	-1.0652	0.0001
	Creatinine	HMDB00562	0.9127	0.0279
	DL-Dopa	HMD800609	9.2555	0.0006
*	Glutamate	HMDB03339	1.4051	0.0061
nine	Histamine	HMDB00870 HMDB00177	1 2071	0.0455
ic An	Hydroxyproline	HMD800725	0.7219	0.0007
geni	Isoleucine	HMD633923	1.1391	0.0000
Biol	Leucine	HMD800687	1.0054	0.0000
and	L-Methionine	HMD800696	1.2330	0.0001
cids	Lysine Mathianing sufferride	HMDB00182	0.4621	0.0002
٩.	Ornithine	HMDB02005	-0.5066	0.0000
- E	Phenylalanine	HMD800159	1.5345	0.0000
~	Phenylethylamine	HMD612275	-3.0357	0.0002
	Proline	HMDB00162	1.2959	0.0000
	Sarcosine Summatrix dismath demining	HMD600271	0.9071	0.0061
	Symmetric dimethylarginine Taurine	HMD803334 HMD800251	0.9805	0.0008
	Threonine	HMD800167	0.4729	0.0238
	Tryptophan	HMD613609	0.9721	0.0000
	Tyrosine	HMD600158	1.7499	0.0000
	Valine	HMD800883	0.6463	0.0000
He Acids	Taurocholic acid Dorosanentaenois acid (32n-6)	HMD600036 HMD901976	-2.3168	0.0005
	Elcosadienoic acid	HMDB01976	-0.5682	0.0000
-6	Elcosatrienoic acid	HMDB02925	-1.4250	0.0230
Aci	Gamma-Linolenic acid	HMDB03073	-5.0038	0.0004
atty	Hexadecanoic acid	HMDB00220	-0.6293	0.0052
<u></u>	Linoleic acid	HMDB00673	-2.9727	0.0008
	Tetradecanoic acid	HMDB00827 HMDB00806	-2.3367	0.0000
lexose	Hexose	HMD800143	1.8148	0.0000
	lysoPhosphatidylcholine acyl C17:0	HMD612108	1.1756	0.0000
	lysoPhosphatidylcholine acyl C18:0	HMDB10384	0.9446	0.0005
	lysoPhosphatidylcholine acyl C18:1	HMDB02815	1 1955	0.0004
	lysoPhosphatidylcholine acyl C20.3	HMDB10393	-0.4999	0.0022
	lysoPhosphatidylcholine acyl C20:4	HMDB10395	-0.6118	0.0024
	lysoPhosphatidyIcholine acyl C28:0	HMD629206	-0.3863	0.0214
	PC(o-14:0/16:1(92))	HMD613402	-0.7107	0.0000
	PC(0-16:0/16:1(92))	HMD613404	-0.3/14	0.0013
	PC(0-16:0/18:2/9Z.12Z))	HMD611151	-0.9145	0.0000
	PC(o-16:0/20:4(82,112,142,172))	HMDB13407	-0.2094	0.0045
	PC(o-16:1(9Z)/14:1(9Z))	HMD613410	-0.5258	0.0001
	PC[o-16:1(92)/18:2[92,122)]	HMD613413	-0.8547	0.0000
	PC(0-16:1[92]/20:4(82,112,142,172])	HMD613415	0.3913	0.0002
	PC(0-18:0/20:0) PC(0-18:1(97)/16:0)	HMD813415	-0.5417	0.0000
	PC(o-18:1(92)/18:0)	HMDB13427	-0.3007	0.0052
	PC(o-18:1(9Z)/18:1(11Z))	HMDB13428	-0.4857	0.0000
	PC(o-18:1(92)/20:0)	HMDB13430	-0.2872	0.0105
	PC(0-18:1(92)/20:4(82,112,142,172)) PC(0,18:1(92)/22:0)	HMDB13432	0.1359	0.0355
	PC(0-18-2(97,127)/20:0)	HMDB13435	-0.5724	0.0023
	PC(o-18:2(9Z,12Z)/22:0)	HMDB13437	-0.3061	0.0114
	PC(o-20:0/18:3(9Z,12Z,15Z))	HMDB13440	-0.2194	0.0032
	PC(o-20.0/20:4(82,112,142,172))	HMDB13442	-0.4996	0.0000
	PC(o-20:0/22:0) PC(o-20:1(117)/20:4/97:117:147:17***	HMD613443	0.2918	0.0809
	PC[0-22:0/18:3(9Z.12Z.15Z))	HMD613446	-0.6174	0.0000
	PC(o-22:0/20:1(11Z))	HMDB13447	-0.5841	0.0010
ş	PC(o-22:0/20:4(82,112,142,172))	HMDB13448	-0.3539	0.0006
tofin	PC(o-22:0/22:3(102,132,162))	HMDB13449	-0.4941	0.0000
tylch	PC(o-22:1(132)/20:4(82,112,142,172))	HMD613451	-0.5630	0.0000
hatic	PC(0-22:3(102,132,162)/22:3(102,132,162)) PC(0-22:3(102,132,162)/22:3(102,132,162))	HMDB13453	-0.3720	0.0019
dso	PC(o-24:0/18:3(9Z,12Z,15Z))	HMDB13459	-0.3598	0.0015
Æ	Phosphatidylcholine diacyl C24:0	NA	0.8301	0.0000
	Phosphatidylcholine diacyl C26:0	HMD807867	-0.2782	0.0731
	Phosphatidylcholine diacyl C30:0	HMD807999	-0.4155	0.0034
	Phosphatidylcholine diacyl C320	HMD607872	-0.5876	0.0000
	Describetiskskeling diand (22.1	HMD807874	-0.3257	0.0046
	Phosphadoyicionite diacyi Coz.1		-1.2280	0.0000
	Phosphatidylcholine diacyl C32:3	HMD807971		
	Phosphatidylcholine diacyl C32:1 Phosphatidylcholine diacyl C32:3 Phosphatidylcholine diacyl C34:1	HMD807971 HMD807973	-1.2894	0.0000
	Phosphatidylcholine diacyl C32.1 Phosphatidylcholine diacyl C32.3 Phosphatidylcholine diacyl C34:1 Phosphatidylcholine diacyl C34:2 Phosphatidylcholine diacyl C34:4	HMD807971 HMD807973 HMD807974 HMD807986	-1.2894 -0.3524 0.4607	0.0000
	Phosphatidylcholine diacyl C32:1 Phosphatidylcholine diacyl C32:3 Phosphatidylcholine diacyl C34:1 Phosphatidylcholine diacyl C34:2 Phosphatidylcholine diacyl C36:0	HMD807971 HMD807973 HMD807974 HMD807886 HMD808037	-1.2894 -0.3524 0.4607 -1.1493	0.0000 0.0211 0.0054 0.0000
	Phosphatoly(Lohime diacy) C22.1 Phosphatidy(Lohime diacy) C32.3 Phosphatidy(Lohime diacy) C34.1 Phosphatidy(Lohime diacy) C34.2 Phosphatidy(Lohime diacy) C34.4 Phosphatidy(Lohime diacy) C36.0 Phosphatidy(Lohime diacy) C36.1	HMD807971 HMD807973 HMD807974 HMD807886 HMD8088037 HMD808593	-1.2894 -0.3524 0.4607 -1.1493 -1.0715	0.0000 0.0211 0.0054 0.0000 0.0000
	Phosphatalytohime diasy C323 Phosphatalytohime diasy C323 Phosphatalytohime diasy C324 Phosphatalytohime diasy C324 Phosphatalytohime diasy C324 Phosphatalytohime diasy C326 Phosphatalytohime diasy C326 Phosphatalytohime diasy C326 Phosphatalytohime diasy C326	HMD807971 HMD807973 HMD807974 HMD807886 HMD808037 HMD80593 HMD80593 HMD80593	-1.2894 -0.3524 0.4607 -1.1493 -1.0715 -0.9525 0.7005	0.0000
	Prosphatolytohine disc) (32.3 Phosphatolytohine disc) (32.3 Phosphatolytohine disc) (34.1 Phosphatolytohine disc) (34.2 Phosphatolytohine disc) (34.2 Phosphatolytohine disc) (36.1 Phosphatolytohine disc) (36.1 Phosphatolytohine disc) (36.2 Phosphatolytohine disc) (36.2 Pho	HMD807971 HMD807973 HMD807974 HMD807886 HMD808037 HMD805939 HMD805993 HMD807980 HMD807980 HMD807980	-1.2894 -0.3524 0.4607 -1.1493 -1.0715 -0.9525 -0.7905 0.3340	0.0000
	Phosphatidyl ubrain diacy C32:1 Phosphatidyl ubrain diacy C32:2 Phosphatidyl ubrain diacy C34:2 Phosphatidyl ubrain diacy C34:2 Phosphatidyl ubrain diacy C34:2 Phosphatidyl ubrain diacy C36:0 Phosphatidyl ubrain diacy C36:2 Phosphatidyl ubrain diacy C36:3 Phosphatidyl ubrain diacy C36:3 Phosphatidyl ubrain diacy C36:3 Phosphatidyl ubrain diacy C36:3	HMXB607971 HMXB607973 HMXB607973 HMXB607974 HMXB607974 HMXB607985 HMXB607980 HMXB607980 HMXB607980 HMXB607984 HMXB607984	-1.2894 -0.3524 0.4607 -1.1499 -1.0715 -0.9525 -0.7905 -0.3340 -1.3446	0.0000 0.0211 0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
	Phophatalyi Unit and Bay, 122:1 Phophatalyi Unit and Bay, 123:1 Phophatalyi Unit and Bay, 123:1 Phophatalyi Unit and Bay, 123:4 Phophatalyi Unit and Bay, 123:4 Phophatalyi Unit and Bay, 123:6 Phophatalyi Unit and Bay, 123:1	HMD807971 HMD807973 HMD807974 HMD807986 HMD807886 HMD807980 HMD807980 HMD807980 HMD807984 HMD807984 HMD807884 HMD807894	-1.2894 -0.3524 -0.3524 -1.1493 -1.0715 -0.9525 -0.7905 -0.3340 -1.3446 -0.9515	0.0000 0.0211 0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
	Prosphatelycholine diay, C23 Phosphatelycholine diay, C34 Phosphatelycholine diay, C34 Phosphatelycholine diay, C34 Phosphatelycholine diay, C36 Phosphatelycholine diay, C36 Phosphatelycholine diay, C36 Phosphatelycholine diay, C36 Phosphatelycholine diay, C36 Phosphatelycholine diay, C38 Phosphatelycholine diay, C38 Phosphatelycholine diay, C38	HVD807971 HVD807973 HVD807973 HVD807986 HVD807986 HVD807980 HVD807980 HVD807982 HVD807984 HVD807984 HVD807984 HVD807988	-1.2894 -0.3524 -0.4607 -1.1493 -1.0715 -0.9525 -0.7905 -0.3340 -1.3440 -0.9515 -0.9545 -0.9545	0.0000 0.0211 0.0054 0.0000 0.0
	Propublicly/column asso (23) Propublicly/column asso (23) Propublicly/column asso (24) Propublicly/column asso (24)	HMD807971 HMD807973 HMD807973 HMD807974 HMD807974 HMD807986 HMD807980 HMD807980 HMD807984 HMD807984 HMD807984 HMD807984 HMD807989 HMD807989 HMD807989 HMD807989 HMD807989	-1.2894 -0.5524 -0.4607 -1.1493 -1.0715 -0.9505 -0.7905 -0.3340 -1.3446 -0.9515 -0.7020 -0.7020 -0.6717 -0.6519	0.0000 0.0211 0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
	Propublished Holizmi ellion (2013) Prozphałdycholizmi ellion (2014) Prozphałdycholizmi ellion (2015) Prozphałdycholizmi ellion (2015)		-1.2894 -0.3524 0.4607 -1.1493 -1.0715 -0.5525 -0.7905 -0.3340 -1.3446 -0.5515 -0.7520 -0.7517 -0.6717 -0.6559 -0.372	0.0000 0.0211 0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
	Proceedings of the second seco	<ul> <li>НАОБОТУТ1.</li> <li>НАОБОТУТ3.</li> <li>НАОБОТУТ3.</li> <li>НАОБОТУТ3.</li> <li>НАОБОТУТ3.</li> <li>НАОБОТУТ4.</li> <li>НАОБОТУТ4.</li> <li>НАОБОТУ86.</li> </ul>	-1.2894 -0.3524 -0.4607 -1.1493 -1.0715 -0.9525 -0.7905 -0.7905 -0.3340 -1.3446 -0.9515 -0.702 -0.6717 -0.6569 -0.3072 -0.3708	0.0000 0.0211 0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
	Proceedings of the second seco	HADD0771     HADD0773     HADD0773     HADD0773     HAD00774     HAD00774     HAD00784     HAD00503     HAD00503     HAD00503     HAD00503     HAD00503     HAD00786     HAD00786     HAD00786     HAD00786     HAD00786     HAD00788     HAD00789	-1.2894 -0.3524 -0.4607 -1.1493 -0.9525 -0.7955 -0.3340 -1.3446 -0.9515 -0.7020 -0.6559 -0.6559 -0.3772 -0.7088 -1.0530	0.0000 0.0211 0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
	Proceedings of the second seco	HARD07371     HARD07373     HARD07373     HARD07373     HARD07374     HARD07374     HARD07386     HARD07386     HARD07389     HARD07391     HARD07393     HARD0739     HARD0739     HARD0739     HARD0739     HARD0739     HARD0739     HARD0739     HARD0739     HARD073	-1.2894 -0.3524 -0.4507 -1.1493 -1.0715 -0.9525 -0.3300 -1.3446 -1.3446 -0.9515 -0.7020 -0.36717 -0.66717 -0.66717 -0.66717 -0.66788 -0.3072 -0.7088 -0.3072 -0.7088 -0.3072	0.0000 0.0211 0.0054 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
	Proceedings of the second seco	HADD0771     HADD0773     HADD0773     HADD0773     HAD00774     HAD00774     HAD00786     HAD005037     HAD005037     HAD005039     HAD005039     HAD00789     HAD00789     HAD00789     HAD00789     HAD00799     HAD00799     HAD00799     HAD00799     HAD00799     HAD005046     HAD00504     HA	-1.2894 -0.3524 -0.4607 -1.1493 -1.1493 -0.7905 -0.7905 -0.3340 -1.3446 -0.7915 -0.7020 -0.6717 -0.6769 -0.3772 -0.6769 -0.3772 -0.7788 -1.0530 -0.7028 -0.7028 -0.7295 -0.8942 -0.7295 -0.894 -0.7295 -0.894 -0.7295 -0.894 -0.7295 -0.729 -0.7295 -0.7295 -0.729 -0.7295 -0.729 -0.7295 -0.729 -0.729 -0.7295 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.729 -0.72 -0	0.0000 0.0211 0.0054 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000000
	Proceedings of the second seco		-1.2894 -0.3524 -0.407 -1.1493 -1.0715 -0.5525 -0.3540 -0.7505 -0.3400 -1.3446 -0.9515 -0.7020 -0.6717 -0.6797 -0.3072 -0.7796 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.7795 -0.3072 -0.3795 -0.3072 -0.3072 -0.795 -0.3072 -0.307 -0.3072 -0.3072 -0.3072 -0.3072 -0.3072 -0.307 -0.3072 -0.3072 -0.3072 -0.3072 -0.3072 -0.3072 -0.3072 -0.3072 -0.3072 -0.307 -0.30	0.0000 0.0211 0.0054 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000000
	Proceedings of the second seco		-1.2894 -0.3524 -0.3524 -0.3524 -0.3524 -0.354 -0.7955 -0.7905 -0.3340 -0.3340 -0.3346 -0.9515 -0.3702 -0.6769 -0.3072 -0.6769 -0.3072 -0.7728 -0.7728 -0.7728 -0.8842 -0.7286 -0.8842 -0.7688 -0.6686 -0.6688 -0.668 -0.66	0.0000 0.0211 0.0054 0.0000
	Proceedings of the second seco	HADD0771           HADD0773           HADD0774           HADD0774           HADD0774           HADD0774           HADD0774           HADD0774           HADD0774           HADD0774           HADD0774           HADD0778           HAD0078           HAD0078           HAD0078           HAD0078           HAD0078           HAD0078           HAD00795           HAD00795           HAD00876           HAD088054           HAD088057	1.2894 1.2394 1.03524 0.4607 1.1493 1.0175 0.9525 0.9505 0.3346 0.9515 0.7020 0.06717 0.06717 0.0672 0.0370 0.0708 1.0530 0.0307 0.0708 0.0775 0.0375 0.0307 0.0375 0.0412 0.0375 0.0886 0.088 0.08	0.0000 0.0211 0.0020 0.00000 0.000000
	Proceedings of the second seco	HADD0771           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0774           HADD0774           HADD0774           HADD0774           HADD07780           HADD07780           HADD07781           HADD07784           HAD007784           HAD007784           HAD007784           HAD007785           HAD007785           HAD000786           HAD000786           HAD000074           HAD000074           HAD0000074           HAD0000074           HAD0000074           HAD0000074           HAD0000074           HAD0000074           HAD0000074           HAD0000074           HAD0000074           HAD0000075           HAD0000074           HAD0000074           HAD0000075           HAD0000074           HAD0000074           HAD0000075           HAD0000075           HAD0000074           HAD0000075	-1.2894 -0.3524 -0.3524 -0.3524 -0.3524 -0.3544 -0.7955 -0.7955 -0.7955 -0.7955 -0.7955 -0.7955 -0.7955 -0.7955 -0.7955 -0.7957 -0.6259 -0.6259 -0.7755 -0.8042 -0.7755 -0.8042 -0.7755 -0.8042 -0.8085 -0.8085 -1.1958 -1.1988 -1.	0.0000 0.0211 0.0054 0.00000 0.000000
	Proceedings of the second seco	HADD0771           HADD0771           HADD0773           HADD0774           HADD0778           HADD0778           HADD0778           HAD00778           HAD00778           HAD00778           HAD000778           HAD0000778           HAD0000778           HAD0000778           HAD00000778           HAD00000778           HAD00000778           HAD00000778           HAD00000778           HAD000000778           HAD0000000778           HAD000000077	-1.2894 -0.3524 -0.3524 -0.3524 -0.3524 -0.3524 -0.3545 -0.7555 -0.7555 -0.7555 -0.7555 -0.7755 -0.3775 -0.3788 -0.3775 -0.3788 -0.3775 -0.3788 -0.3775 -0.3888 -0.3888 -0.3888 -0.31888 -0.31888 -0.3195 -0.3195 -0.3195 -0.3788 -0.3788 -0.3888 -0.3195 -0.3195 -0.3195 -0.3888 -0.3195 -	0.0000 0.0211 0.0054 0.0000
	Proceedings of the second seco		1.2894 0.457 0.4524 0.457 0.457 0.457 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.955 0.972 0.0708 0.0772 0.0708 0.0772 0.0778 0.0772 0.0804 0.775 0.0804 0.775 0.0804 0.755 0.0804 0.0804 0.755 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.0804 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75	0.00000 0.0211 0.0054 0.0000 0.000000
	Proceedings of the second seco		-1.284 -0.554 -0.554 -0.554 -0.554 -1.1493 -0.775 -0.755 -0.765 -0.766 -0.334 -1.444 -0.0347 -1.444 -0.0575 -0.707 -0.667 -0.707 -0.667 -0.707 -0.667 -0.707 -0.667 -0.709 -0.667 -0.729 -0.410 -0.420	0.0000 0.0211 0.0054 0.00000 0.00000 0.00000 0.00000 0.000000
19	Proceedings of the second seco	HANDB0771           HANDB0773           HANDB0773           HANDB0773           HANDB0773           HANDB0774           HANDB0774           HANDB0774           HANDB0774           HANDB0774           HANDB0774           HANDB07780           HANDB07781           HANDB07781           HANDB07784           HANDB07784           HANDB07784           HANDB07784           HANDB07784           HANDB07784           HANDB07784           HANDB07784           HANDB07785           HANDB07781           HANDB0781           HANDB0782           HANDB0805           HANDB08028           HANDB08028           HANDB08028           HANDB08028           HANDB08028           HANDB08028           HANDB08028	-1.2894 -0.554 -0.5574 -0.5574 -0.5574 -0.5574 -0.5575 -0.555 -0.	0.00000 0.0211 0.00545 0.000000
solipid	Prosphatelytokine elion (2013) Prosphatelytokine elion (2014) Prosphatelytokine elion (2014)	HADD0771           HADD0771           HADD07731           HADD07781           HADD07784           HADD07784           HADD07784           HADD07784           HADD07784           HADD07784           HADD08057           HADD08057           HAD08057           HAD081142           HAD08144           HAD08144           HAD08144           HAD08144           HAD08144           HAD08144     <	-1.2894 -0.5524 -0.5524 -0.5524 -0.5524 -0.5524 -0.5554 -0.5555 -0.755 -0.7555 -0.7555 -0.7555 -0.7555 -0.7555 -0.7555 -0.7555 -0.7555 -0.755	0.0000 0.0211 0.0054 0.00000 0.00000 0.00000 0.00000 0.000000
hhngolipid	Proceedings of the second seco	HADD0771           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0774           HADD0774           HADD0774           HADD0774           HADD07780           HADD07780           HADD07781           HADD07784           HADD07784           HAD007784           HAD007784           HAD007784           HAD007784           HAD007784           HAD000784           HAD0007784           HAD000784           HAD000074           HAD000074           HAD000074           HAD000074           HAD0000074	-1.2994 0.0554 0.0554 0.0554 0.0554 0.0554 0.0554 0.0554 0.0554 0.0556 0	0.0000 0.0211 0.0054 0.00000 0.00000 0.00000 0.00000 0.000000
sphireolipid	Proceedings of the second seco	никоволя/1	-1.2894 -0.5524 -0.5524 -0.5524 -0.5524 -0.5524 -0.5554 -0.5554 -0.5555 -0.555	0.0000 0.0211 0.0054 0.00000 0.00000 0.00000 0.00000 0.000000
sphingolipid	Proceedings of the second seco	HADD0771           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0773           HADD0774           HADD0774           HADD0774           HADD0774           HADD07780           HADD07780           HADD07781           HADD07784           HADD07784           HAD007784           HAD007784           HAD007784           HAD007784           HAD000788           HAD000788           HAD000788           HAD000784           HAD0000784           HAD0000784           HAD0000784           HAD00000784           HAD00000784           HAD00000784           HAD000000784           HAD00000000784           HAD000000	-1.2894 -0.554 -0.554 -0.554 -0.554 -0.554 -0.555 -0.555 -0.555 -0.55 -0	0.0000 0.0211 0.0211 0.0054 0.00000 0.00000 0.00000 0.00000 0.00000 0.000000



for caged and wild goldfish plasma at wastewater-exposed CPM sites compared to the reference JH. The targeted metabolomics data better predicted responses in wild goldfish than did the untargeted protein data (79% versus 57%, Fig. 6), which is likely explained by the higher variation that accompanies untargeted approaches<sup>21</sup>. The advantage of untargeted approaches are that they are less biased, however they come with the cost of lowered

		<b>Biological Function</b>	Activation z-score	p-alue	# Mols	Molecules			
		synthesis of cyclic AMP	-2.501	1.48E-04	7	2-phenethylamine,5-hydroxytryptamine,cholic acid,histamine,palmitic acid,taurochenodeoxycholate,taurocholic acid			
		biosynthesis of cyclic nucleotides	-2.028	4.35E-05	8	2-phenethylamine,5-hydroxytryptamine,cholic acid,histamine,myristic acid,palmitic acid,taurochenodeoxycholate,taurocholic acid			
	CPM1	efflux of neutral amino acid	-2	1.04E-07	4	glycine,L-leucine,L-serine,L-threonine			
		efflux of L-amino acid	-2	2.46E-06	4	glycine,L-leucine,L-serine,L-threonine			
		cell death of liver cells	2.374	5.53E-06	8	arachidonic acid,cholic acid,glycine,histamine,L-arginine,palmitic acid,SPTBN1,taurine			
		necrosis of liver	2.326	2.55E-07	10	arachidonic acid,C3,cholic acid,glycine,histamine,L-arginine,L-phenylalanine,palmitic acid,SPTBN1,taurine			
		quantity of Ca2+	2.253	8.60E-13	20	(all Z)-7,10,13,16,19-docosapentaenoic acid,5-hydroxytryptamine,9Z-hexadecenoic acid,adrenic acid,arachidonic acid,C3,CRACR2A,docosahexaenoic acid,eicosa-11Z, 14Z-dienoic acid,FN1,GABA,gamma-linolenic acid,glycine,histamine,icosapent,L-lysine,L-ornithine,myristic acid,NPHS1,palmitic acid			
		cell death of hepatocytes	2.185	1.00E-05	7	arachidonic acid,cholic acid,glycine,histamine,L-arginine,palmitic acid,SPTBN1			
		quantity of metal	2.091	2.78E-13	22	(all Z)-7,10,13,16,19-docosapentaenoic acid,5-hydroxytryptamine,9Z-hexadecenoic acid,adrenic acid,arachidonic acid,C3,CRACR2A,docosahexaenoic acid,eicosa-11Z, 14Z-dienoic acid,FN1,GABA,gamma-linolenic acid,glycine,histamine,HPX,icosapent,L-lysine,L-ornithine,myri acid,NPHS1,palmitic acid,TF			
C IN L		apoptosis of liver cells	2.023	9.15E-06	7	arachidonic acid,glycine,histamine,L-arginine,palmitic acid,SPTBN1,taurine			
Goldfish		growth of bacteria	-2.739	8.53E-12	12	docosahexaenoic acid,glycine,L-arginine,L-aspartic acid,L-phenylalanine,L-proline,L-serine,L-threonine,L-valine,spermidine,spermine,TF			
		entry into S phase of hepatocytes	-2.236	2.30E-11	5	glycine,L-asparagine,L-aspartic acid,L-proline,L-serine			
		entry into S phase	-2.236	2.52E-05	6	FN1,glycine,L-asparagine,L-aspartic acid,L-proline,L-serine			
		export of molecule	-2.047	2.31E-07	12	arachidonic acid,cholic acid,docosahexaenoic acid,GABA,glycine,L-aspartic acid,L-leucine,L-serine,L-threonine,spermine,sphingomyelin,taurocholic acid			
		growth of organism	-2.043	2.78E-04	14	docosahexaenoic acid, FN1,GABA,glycine,L-arginine,L-aspartic acid,L-phenylalanine,L-proline,L- serine,L-threonine,L-valine,spermidine,spermine,TF			
	CPM2	excitation of orexin neurons	-2	6.17E-08	4	glycine,L-aspartic acid,L-proline,L-serine			
		efflux of neutral amino acid	-2	8.89E-08	4	glycine,L-leucine,L-serine,L-threonine			
		efflux of L-amino acid	-2	2.10E-06	4	glycine,L-leucine,L-serine,L-threonine			
		uptake of amino acids	3.062	9.63E-16	14	D-tryptophan,GABA,glycine,isoleucine,L-aspartic acid,L-phenylalanine,L-serine,L-threonine,L-tyrne,sarcosine,spermine,taurine,taurocholic acid,trans-4-hydroxy-L-proline			
		uptake of L-amino acid	2.897	1.76E-16	13	D-tryptophan, GABA, glycine, isoleucine, L-aspartic acid, L-phenylalanine, L-serine, L-threonine, L-tyrosine, sarcosine, spermine, taurine, trans-4-hydroxy-L-proline			
		uptake of L-alanine	2.449	4.94E-11	6	glycine,isoleucine,L-phenylalanine,L-serine,L-threonine,L-tyrosine			
		blood pressure	2.138	1.03E-04	8	5-hydroxy tryptamine, a rachidonic acid, GABA, glycine, histamine, L-arginine, L-lysine, L-ornithine acid, GABA, glycine, histamine, a rachidonic acid, GABA, glycine, histamine, histami			
	CDM2	uptake of glutamine family amino acid	2.121	1.64E-10	9	D-tryptophan,GABA,glycine,L-aspartic acid,L-phenylalanine,sarcosine,spermine,taurine,trans-4- hydroxy-L-proline			
	CI MIZ	transport of amino acids	2.053	1.12E-15	16	D-tryptophan,GABA,glycine,isoleucine,L-aspartic acid,L-leucine,L-lysine,L-phenylalanine,L- serine,L-threonine,L-tyrosine,sarcosine,spermine,taurine,taurocholic acid,trans-4-hydroxy-L-proline			
		growth of organism	-2.554	2.11E-04	14	docosahexaenoic acid,FN1,GABA,glycine,L-arginine,L-aspartic acid,L-phenylalanine,L-proline,L-serine,L-threonine,L-valine,spermidine,spermine,TF			
		synthesis of cyclic AMP	-2.501	9.78E-05	7	2-phenethylamine,5-hydroxytryptamine,cholic acid,histamine,palmitic acid,taurochenodeoxycholate,taurocholic acid			
		quantity of steroid	-2.306	8.22E-05	11	5-hydroxytryptamine,acetyl-L-carnitine,arachidonic acid,carnosine,cholic acid,docosahexaenoic acid,EPM2A,histamine,palmitic acid,sphingomyelin,taurine			
		transport of molecule	-2.279	1.58E-11	33	2-phenethylamine,5-hydroxytryptamine,arachidonic acid,C3,cholic acid,creatinine,D- tryptophan,docosahexaenoic acid,FGG,FN1,GABA,glycine,HBB,histamine,HPX,isoleucine,L-aspartic acid,L-leucine,L-lysine,L-phenylalanine,L-serine,L-threonine,L-tyrosine,myristic acid,palmitic acid,sarcosine,spermine,sphingomyelin,taurine,taurochenodeoxycholate,taurocholic acid,TF,trans-4- hydroxy-L-proline			
		release of acidic amino acid	-2.219	2.25E-06	6	2-aminoadipic acid,5-hydroxytryptamine,GABA,glycine,histamine,L-arginine			
Caged Male		release of L-amino acid	-2.219	2.62E-06	6	2-aminoadipic acid,5-hydroxytryptamine,GABA,glycine,histamine,L-arginine			
Goldfish		Fibrosis	-2.219	3.42E-03	9	C3, cholic acid, docosahexaenoic acid, FN1, GABA, HBB, HPX, L-arginine, taurine			
	СРМ3	growth of bacteria	-2.191	6.30E-12	12	docosahexaenoic acid,glycine,L-arginine,L-aspartic acid,L-phenylalanine,L-proline,L-serine,L-threonine,L-valine,spermidine,spermine,TF			
		exocytosis	-2.162	1.32E-03	5	arachidonic acid,FGG,glycine,histamine,spermine			
		proliferation of cells	-2.073	3.12E-03	31	2-phenethylamine,5-hydroxytryptamine,arachidonic acid,C3,cholic acid,DAB2IP,docosahexaenoic acid,FN1,GABA,gamma-linolenic acid,glycine,histamine,HPX,L-arginine,L-asparagine,L-aspartic acid,L-lysine,L-phenylalanine,L-proline,L-serine,L-threonine,L-valine,myristic acid,palmitic acid,sarcosine,SERPINA1,SERPINA5,spermidine,spermine,taurocholic acid,TF			
		biosynthesis of cyclic nucleotides	-2.028	2.70E-05	8	2-phenethylamine,5-hydroxytryptamine,cholic acid,histamine,myristic acid,palmitic acid,taurochenodeoxycholate,taurocholic acid			
		efflux of neutral amino acid	-2	7.98E-08	4	glycine,L-leucine,L-serine,L-threonine			
		efflux of L-amino acid	-2	1.89E-06	4	glycine,L-leucine,L-serine,L-threonine			
		accumulation of acylglycerol	2.162	6.93E-05	5	arachidonic acid,cholic acid,L-arginine,myristic acid,palmitic acid			
		accumulation of lipid	2.044	2.18E-06	11	5-hydroxytryptamine,arachidonic acid,cholic acid,docosahexaenoic acid,FN1,L-arginine,L- serine,myristic acid,palmitic acid,sphingomyelin,taurine			
Continued									

	Biological Function	Activation z-score	p-alue	# Mols	Molecules			
	uptake of L-amino acid	-2.985	1.17E-10	10	D-tryptophan,isoleucine,L-histidine,L-methionine,L-phenylalanine,L-threonine,L- tyrosine,sarcosine,taurine,trans-4-hydroxy-L-proline			
	apoptosis	-2.86	3.48E-03	28	A2M,acetyl-L-carnitine,APOA1,CALCR,HBA1/HBA2,histamine,IKBKAP,IRF2BP2,KLHL20,L- arginine,L-histidine,L-methionine,L-phenylalanine,L-tyrosine,linoleic acid,MCL1,myristic acid,N,N- dimethylarginine,palmitic acid,PCP4,PKM,RBP3,RYR2,SERPINA1,stearic acid,taurine,TF,ULK2			
CDM Weld Mele	cell death	-2.45	3.06E-03	34	2-aminoadipic acid,A2M,acetyl-L-carnitine,APOA1,CALCR,CLDN4,colfoscer il palmitate,FETUB,HBA1/HBA2,histamine,IKBKAP,IRF2BP2,KLHL20,L-arginine,L- histidine,L-methionine,L-phenylalanine,L-tyrosine,linoleic acid,MCL1,myristic acid,N,N- dimethylarginine,NEFH,palmitic acid,PCP4,PKLR,PKM,RBP3,RYR2,SERPINA1,stearic acid,taurine,TF,ULK2			
Goldfish	uptake of L-alanine	-2.449	1.71E-10	6	isoleucine,L-histidine,L-methionine,L-phenylalanine,L-threonine,L-tyrosine			
	uptake of amino acids	-2.373	2.62E-10	11	D-tryptophan,isoleucine,L-histidine,L-methionine,L-phenylalanine,L-threonine,L-tyrosine,sarcosine, taurine,taurocholic acid,trans-4-hydroxy-L-proline			
	organismal death	-2.346	4.79E-03	25	2-phenethylamine,A2M,APOA1,CALCR,CLDN4,creatinine,FGG,gamma-linolenic acid,HBZ,histamine,IKBKAP,L-arginine,L-phenylalanine,linoleic acid,LRP4,MCL1,myristic acid,palmitic acid,PKM,RYR2,SERPINA1,stearic acid,TF,TRIP12,ULK2			
	quantity of Ca2+	-2.202	2.90E-06	13	A2M,CALCR,gamma-linolenic acid,HBA1/HBA2,histamine,L-lysine,L-ornithine,linoleic acid,MCL1,myristic acid,palmitic acid,RYR2,stearic acid			
	quantity of metal	-2.148	8.98E-07	15	A2M,CALCR,gamma-linolenic acid,HBA1/HBA2,histamine,HPX,L-lysine,L-ornithine,linoleic acid,MCL1,myristic acid,palmitic acid,RYR2,stearic acid,TF			
	synthesis of lipid	-2.092	2.15E-03	12	APOA1,histamine,L-arginine,L-methionine,linoleic acid,myristic acid,palmitic acid,PKM,SERPINA1,ST8SIA5,stearic acid,taurocholic acid			
	accumulation of lipid	-2.037	2.69E-03	7	APOA1,L-arginine,linoleic acid,myristic acid,palmitic acid,stearic acid,taurine			
	uptake of L-proline	-2	8.48E-07	5	D-tryptophan,L-phenylalanine,sarcosine,taurine,trans-4-hydroxy-L-proline			
	proliferation of CD4+ T-lymphocytes	-2	1.71E-04	4	gamma-linolenic acid,linoleic acid,palmitic acid,stearic acid			
CPM Wild Male	cell survival	2.872	3.46E-04	20	CALCR,CLDN4,gamma-linolenic acid,HBA1/HBA2,HBZ,histamine,isoleucine,L- arginine,L-histidine,L-methionine,L-proline,LEO1,MCL1,NEFH,palmitic acid,PKLR,PKM,RARRES3,RYR2,stearic acid			
Goldfish	cell viability	2.733	3.77E-04	19	CALCR,CLDN4,gamma-linolenic acid,HBA1/HBA2,HBZ,histamine,isoleucine,L-arginine,L- histidine,L-methionine,L-proline,MCL1,NEFH,palmitic acid,PKLR,PKM,RARRES3,RYR2,stearic acid			
	incorporation of thymidine	2.438	8.14E-06	6	L-methionine,linoleic acid,myristic acid,palmitic acid,stearic acid,TF			
	concentration of glutathione	2.042	1.02E-06	7	acetyl-L-carnitine,citrulline,gamma-linolenic acid,L-arginine,L-methionine,PKM,taurine			
	oxidation of glucose-6- phosphate	2	2.00E-08	4	linoleic acid,myristic acid,palmitic acid,stearic acid			
	contractility of heart	2	1.96E-03	5	APOA1,CKM,L-arginine,MCL1,RYR2			

**Table 1.** List of biological functions with activation scores (z-value), p-value, and list of the molecules (either the gene symbol ortholog for proteins or the common name for metabolites) identified as being related to that function.

precision - and while targeted approaches are more precise, they do not capture as much information as untargeted methods. By employing both strategies in the present study (untargeted proteomics and targeted metabolomics), we strived to achieve a balanced design. The magnitude of protein and metabolite expression fold change was greater in wild goldfish compared to the caged goldfish, possibly reflecting that the caged goldfish were exposed for only 21 days in CPM, while the wild goldfish presumably spent much of their lifetime in the marsh and had more time to adjust to their environment. Differences among the three sites were more apparent after functional biological analyses; only 6 out of 43 of the significantly affected biological functions were common to the wild and caged fish. Furthermore, among those 6 common biological functions, all were considered to be significantly activated in the caged fish, but inhibited in wild goldfish on the basis of the IPA derived z-scores.

In the present study, we detected 10 molecules in the plasma of goldfish caged nearest the outflow of the WWTP at CPM1 that were identified by the IPA core analysis as being involved in the activation of liver and liver cell necrosis (Table 1). We also detected 15 PPCPs (out of 127 targets) in the plasma of goldfish caged nearest to the WWTP outfall CPM1<sup>19,20</sup>, among which, 7 were psychotropic drugs or their metabolites (amitrip-tyline, citalopram, fluoxetine/norfluoxetine, sertraline, venlafaxine, and oxazepam) and three were antimicrobials (erythromycin-H<sub>2</sub>O, flumequine, and sulfamethazine)(plasma concentrations of PPCPs are summarized in Table 2). Naproxen and ibuprofen (both non-steroidal anti-inflammatory drugs; NSAIDs) were detected in the water of CPM, but were below detection limits in the plasma. Additionally, the antidepressant drug fluoxetine and the fibrate drug gemfibrozil had the highest bioaccumulation factors (BAFs) in caged and wild goldfish<sup>20</sup>.

The bioaccumulation of the aforementioned drugs in fish indicates that, compared to the other drugs present in the waters of CPM, these drugs are either more bioavailable or not metabolized as quickly; or, are both more bioavailable and slowly metabolized. Being nearly 100% bioavailable in humans, gemfibrozil is an established cytochrome P450 (CYP450) inhibitor, and this inhibition is thought to reduce the metabolism of other drugs<sup>22</sup>. In the yellow European eel (*Anguilla anguilla*), CYP1A activity was inhibited 96 hr after injection with gemfibrozil<sup>23</sup>. Erythromycin and sulphonamides (such as sulfamethazine) are also known to inhibit CYP450 activity<sup>24</sup>. In zebrafish liver microsomes, a mixture of gemfibrozil, erythromycin, ciprofloxacin and fluoxetine inhibited CYP450-mediated reactions<sup>25</sup>. Gemfibrozil, fluoxetine, sulfamethazine, and erythromycin were detected in the plasma of our goldfish. Thus, we suspect the bioaccumulation of the PPCPS in fish from the present study was influenced by reduced metabolism, which might have been exasperated by inhibition of CYP450 phase-I metabolism by other drugs present in the mixture.

Reduced drug metabolism can cause drug-induced liver injury (DILI) in humans<sup>24,26,27</sup>. DILI accounts for over 50% of acute liver failure cases in the USA<sup>24</sup>. Anti-infectious agents, psychotropic drugs, and NSAIDs were among the most common culprits causing DILI at rates of 25%, 22.5%, and 10%, respectively, among all reported DILI cases over a 3-yr period in France<sup>27</sup>. The mechanisms of DILI generally involve mitochondrial dysfunction or induction/inhibition of cytochrome P450 isoenzymes<sup>26</sup>. In both cases, metabolic cholestasis can occur, resulting in an increase of cellular reactive oxygen species (ROS) and the loss of cellular glutathione (GSH) to reduced glutathione (GSSH) which can interfere with drug metabolism and clearance<sup>26,28</sup>. Although we did not directly measure ROS, GSH, or GSSH in this present study, the IPA software predicted that expression of glutathione would be activated, based upon the pattern of expression of 7 molecules that were measured in plasma of wild male goldfish from CPM (Table 1). Assuming the IPA prediction was correct, the wild male goldfish from CPM had increased levels of GSH in the liver, in a likely compensatory mechanism to help reduce oxidative stress caused by the impaired metabolism of drugs. Such compensatory mechanisms might also explain the ability of the goldfish caged closest to the Dundas WWTP effluent outfall (CPM1) to survive, despite the presence of expressed proteins and metabolites that are implicated in liver cell necrosis.

Gemfibrozil is designed to decrease accumulation of lipids by activating the peroxisome proliferator-activated receptor-alpha (PPAR $\alpha$ ), which increases the production of lipid metabolizing enzymes. It is possible that gem-fibrozil exposure could have led to altered lipid levels in goldfish from CPM. Based upon expression levels of 13 proteins and metabolites, the IPA analysis predicted inhibition of lipid synthesis and accumulation in wild male goldfish (Table 1), which was supported by the observation of reduced plasma fatty acids, bile acids, and phosphatidylcholines compared to caged goldfish at the reference site (Fig. 5). Inhibited lipid synthesis was further supported by reduced bile acids and fatty acids in caged fish plasma. While concentrations of most fatty acids increased in goldfish caged closest to the WWTP outfall at CPM1, plasma fatty acids then decreased in fish caged further downstream at CPM2 and CPM3 when compared with goldfish caged at the reference site.

The reported effects of gemfibrozil on lipid metabolism in other teleost fish have been variable, but generally support our observations. For example, Skolness et al.<sup>29</sup> observed increased triglycerides in female fathead minnow (Pimephales promelas) after short-term exposure (2d), reduced lipoprotein lipase (lpl) mRNA expression after an intermediate length of time (8d), and increased apolipoprotein A1 (apoa1) mRNA expression after longer term waterborne exposure (21d) at 600 mg gemfibrozil/L<sup>29</sup>. Whereas in male fathead minnow, apoa1 mRNA expression was reduced (8d) and lpl mRNA expression was increased (2d)<sup>29</sup>. Prindiville et al.<sup>30</sup> observed decreased plasma lipid levels and increased hepatic lpl mRNA expression in juvenile female rainbow trout (Oncorhynchus mykiss) following i.p. injection of 100 mg/kg of gemfibrozil every third day for 15 days<sup>30</sup>. In our study, expression of Apoa1 was increased and plasma fatty acids were decreased in wild goldfish (Figs 2 and 5) and fatty acids were also reduced in fish caged at CPM2 and CPM3 (Figs 1 and 4) at gemfibrozil plasma concentrations of 0.15 ng/g and water concentrations ranging from 4.75–41.3 ng/L. Thus, the changes in expression of lipid carrier proteins and lipid molecules that we observed in the goldfish from CPM seem to be typical for fish exposed to gemfibrozil in the laboratory albeit at much higher exposure concentrations (106 times higher than the environmental bioaccumulation in the present study). It could be that goldfish are more sensitive to gemfibrozil than other species, or perhaps we observed a seasonal affect due to consumption of a different diet and nutritional status which may occur during summer months. However, the impact of environmental exposures to gemfibrozil on the long-term health and survival of fish in the wild remains unclear.

#### Conclusions

The PPCPs that were detected in the plasma of caged and wild fish from CPM appear to have had subtle effects, occurring mostly at the molecular level. However, those molecular effects appear to have resulted in altered behaviour, which is discussed in detail in our companion manuscript<sup>19</sup>. The plasma metabolome and proteome responses in caged goldfish near the WWTP outfall at CPM2 and CPM1 most closely predicted the responses in wild goldfish. We observed changes in protein expression and metabolite concentrations that were suggestive of liver necrosis and altered lipid metabolism. These effects could have been caused by exposure to PPCPs present in WWTP effluents, but also could have been influenced by a broader set of pollutants which could also be present in CPM. Despite these apparently adverse indicators, survival was high in caged fish housed for three weeks along the wastewater effluent plume in Cootes Paradise. The expression of plasma metabolites and proteins in caged goldfish agreed well with those in the wild goldfish, suggesting that the combined use of 'omic approaches and caged surrogates is a useful way to predict the molecular effects of contaminants in wild fish. Goldfish are known to be a highly resilient species, and as such, have proven highly successful as invaders of Great Lakes ecosystems<sup>31</sup>. Ultimately, the molecular responses we observed in these robust fish are likely conservative predictors of the potential effects of PPCPs and wastewater effluents on other wild fish species. Our findings suggest that future studies that focus on the mechanisms underlying metabolic disruption in fish exposed to wastewater effluents in the wild are warranted.

#### Methods

All animal experiments were in accordance with CCAC guidance and approved by the GLLFAS-WSTD Animal Care Committee (Government of Canada).

**Wild goldfish collection.** Wild goldfish were collected from CPM in May 2012, by electrofishing by Royal Botanical Gardens staff. Though multiple efforts were made to catch goldfish at the reference site and at other



**Figure 6.** Venn diagrams of either the number of molecules (proteins and metabolites) or the number of biological functions in caged and wild goldfish. Intersections contain the number of molecules or functions that were common to both caged and wild goldfish (highlighted in blue). The word "agree" indicates the number of molecules where the direction of the fold change was the same for both caged and wild goldfish, and the word "disagree" indicates the number of molecules whose expression was in the opposite direction for the caged and wild goldfish. Where there was more than one biological function in an intersection, the number of molecules related to those functions were pooled together to make one Venn diagram for the multiple funcions (quantity of metal and quantity of Ca2+ merged to quantity of metal and Ca2+, and uptake of L-amino acids, uptake of amino acids, and uptake of L-alanine were merged to uptake of amino acids).

nearby locations where they were previously abundant, no wild goldfish were captured at JH in 2012. A map of the caging sites and the wild fish collection areas is shown in Fig. 1.

**Goldfish Caging.** We purchased male goldfish in 2014 from AQUAlity Tropical Fish Wholesale, Inc. (Mississauga, ON) and housed the fish in 1500 L tanks with flow set for 1 L/g of fish/day in the Aquatic Life Research Facility (ALRF) (Environment Canada, Burlington, ON) for 2 weeks before deployment in the cages. Fish were formalin treated and fed with Northfin Goldfish Formula, Canadian Aquatic Feeds Ltd, Toronto at 2% of estimated bodyweight per day.

We constructed cages from Rubbermaid Hinged Top Totes (114 L, Polypropylene, Dimensions:  $81 \times 51.4 \times 44.5$  cm) with drilled holes that were 1.5875 cm in diameter. We modified each with stainless steel hardware to allow for suspension 30.5 cm above the sediment. Each cage housed 13 fish. We visited the cages weekly to feed the fish – 20 g of food per cage. The caged goldfish were deployed for 21 days from June25/26 – July 16/17, 2014. There were five cages at each of four sites, which are described in detail in our companion manuscript<sup>19</sup>. Briefly, three sites were located along the plume of the Dundas WWTP outfall in CPM: CPM1 (nearest to outfall), CPM2 (downstream from CPM1 and upstream of CPM3), and CPM3 (furthest from outfall), and the fourth site, JH, served as a reference site that was located outside of the CPM watershed but further south on Lake Ontario. JH was selected because as the control because we had previously collected water samples from there, and thus we knew the PPCP concentrations from that location (available in Muir *et al.*<sup>20</sup>). Additionally, because we could not capture any wild goldfish from JH in 2012, we elected to use fish caged at JH as a reference to assess the wild fish from CPM in 2012. We considered including a laboratory control, but there is evidence that variation in 'Omics responses are much greater for field than laboratory exposures<sup>21</sup>, and thus laboratory held fish

		JH caged goldfish (n <sub>pooled</sub> =1)	CPM1 caged goldfish (n <sub>pooled</sub> =1)	CPM2 caged goldfish (n <sub>pooled</sub> =1)	CPM3 caged goldfish (n <sub>pooled</sub> =1)	CPM wild goldfish n = 3
PPCP name	Use	ng/g	ng/g	ng/g	ng/g	Mean (range) ng/g
Hydrocortisone*	Steroidal Anti-inflammatory	92.4	100	107	113	127 (118–134)
Sulfamethazine	Antibiotic	<0.12 (bdl)	<0.244 (bdl)	<0.165 (bdl)	<0.123 (bdl)	0.11 (0.07–0.17)
Erythromycin-H2O	Antibiotic	0.23	0.225	0.224	0.495	0.47 (0.23-0.66)
Flumequine	Antibiotic	<0.3 (bdl)	1.1	0.146	0.344	0.57 (0.16–1.37)
Diphenhydramine	Anticholinergic	<0.12 (bdl)	0.23	0.213	0.062	0.15 (0.06-0.25)
Sertraline	Antidepressant	<0.08 (bdl)	0.105	0.039	0.041	0.13 (0.04-0.24)
Venlafaxine	Antidepressant	<0.08 (bdl)	0.165	0.039	0.041	0.11 (0.04–0.26)
ΣAmitriptyline	Antidepressant	<0.06 (bdl)	0.06	0.07	0.05	0.07 (0.04-0.15)
Citalopram	Antidepressant	<0.08 (bdl)	0.1455	0.1625	0.041	0.10 (0.04-0.13)
ΣDiazepam	Antidepressant	0.91	0.81	0.39	0.41	0.89 (0.42–1.34)
ΣFluoxetine	Antidepressant	<0.3 (bdl)	1.18	0.73	0.32	0.92 (0.45-1.50)
Iopamidol	Contrast agent	<16 (bdl)	20.9	17.6	8.20	8.12 (7.85-8.35)
Gemfibrozil	Lipid regulator	<0.3 (bdl)	0.147	0.146	0.154	0.46 (0.15-0.86)
$\Sigma$ Caffeine	Stimulant	<3.0 (bdl)	3.38	1.46	1.54	1.52 (1.47–1.57)
N,N-Diethyl-m-toluamide (DEET)	Repellent	0.235	0.416	0.41	0.314	0.46 (0.23–0.58)

**Table 2.** Blood plasma concentrations of PPCPs in pooled plasma from caged goldfish and individual plasma samples from wild goldfish (adapted from Muir *et al.*<sup>20</sup>). The acronym "bdl" is short for below detection limit.  $\Sigma$ Amitriptyline = sum of amitriptyline and 10-hydroxy-amitriptyline;  $\Sigma$ Caffeine = sum of caffeine + 1,7-dimethylxanthine;  $\Sigma$ Diazepam = sum of diazepam and oxazepam;  $\Sigma$ Fluoxetine = sum of fluoxetine and norfluoxetine. \*likely present as a natural hormone (cortisol).

control might not provide a realistic negative control. Finally, we were confident that we could compare the wild goldfish captured in CPM in 2012 to goldfish caged at CPM in 2014, despite the temporal difference, because the accumulated levels of plasma PPCPs were remarkably similar (close to a factor of 1 and well within a factor of 2 in most cases) (see Table 2).

**Fish samples.** We transported fish from the deployment sites back to the laboratory in bags of aerated, site-specific water. For both wild-captured and field caged fish, they were first anesthetized in an aerated solution of tricaine methanesulfonate (TMS; 50-60 mg/L) that was buffered with NaHCO<sub>3</sub> (100-120 mg/L) (Animal Care Protocol AU1122) in a bath of water taken from each site. We collected blood from the caudal vein, and then separated plasma from blood using a refrigerated centrifuge into cryogenic vials as previously described<sup>32</sup>. Afterward, we immediately froze the plasma vials in liquid nitrogen, and we then stored the plasma at  $-80^{\circ}$ C for future analyses. We then recorded mass and fork length of each fish, euthanized the fish by caudal vein severance and then excised and weighed the gonads from each fish.

**Vitellogenin.** We measured plasma Vtg for 15 caged goldfish at CPM1 and for 15 caged goldfish at JH using an ELISA kit for carp Vtg (Biosense, Cedarlane Labs, Burlington, ON). Plasma was diluted 20x. The ELISA was calibrated against a Carp Vtg standard 62.5–0.06 ng/ml in 12 serial 1:1 dilutions.

**Proteomics.** We thawed plasma samples from individual fish on ice and then transferred 15  $\mu$ L of the plasma into a low-retention micro-centrifuge tube. We digested plasma proteins by formic acid digestion as previously described<sup>32</sup>. Next, we dried the digests to near dryness in a centrifugal evaporator, and then re-constituted the peptides in 20  $\mu$ L of 95:5 Water:Acetonitrile with 0.1% formic acid. We injected 2  $\mu$ L of the peptide solution and then performed a separation by reverse phase liquid chromatography on a Zorbax, 300SB-C18, 1.0 × 50 mm 3.5  $\mu$ m column (Agilent Technologies Canada Inc., Mississauga, ON) using an Agilent 1260 Infinity Binary LC<sup>32</sup>. The Agilent 6520 Accurate-Mass Quadrupole Time of- Flight (Q-TOF) was used as the detector in tandem to the Agilent 1260 system<sup>33</sup>. Each analytical run included a solvent blank, peptide standard (H2016, Sigma-Aldrich, Oakville, ON), and a BSA digest standard (Agilent Technologies Canada Inc, Mississauga, ON) injection every 10 samples in order to monitor baseline, carry-over, drift, and sensitivity during the runtime. We injected once per individual sample.

We identified proteins by search against the National Center for Biotechnology Information (NCBI) Teleostei (teleost fishes) protein database (downloaded March 4, 2015) as previously described<sup>10</sup>. Spectral files for each fish (n = 25) were pooled into groups by location. Each group was analyzed separately using Spectrum Mill Software (Version B.04.01.141). We manually validated and accepted a protein when at least one peptide had a peptide score (quality of the raw match between the observed spectrum and the theoretical spectrum) greater than 5 and a %SPI (percent of the spectral intensity that are accounted for by theoretical fragments) of greater than 60% (these setting are recommended by the manufacturer for validating results obtained with an Agilent Q-TOF mass spectrometer).

**Metabolomics.** We analyzed the plasma metabolome from individual gold fish (2012 field-collected and 2014 caged). AXYS Analytical Services, Ltd (Sidney, BC, CA) carried out the analysis using a targeted metabolomics platform<sup>34</sup> with modifications. The platform contained a total of 217 metabolites including 21 amino acids (AA), 23 biogenic amines (BAs), 13 bile acids,  $\sum$ hexose, 15 fatty acids (FAs), 40 acylcarnitines (ACs), 90 phosphatidylcholines (PCs), and 15 sphingomyelines (SMs) were measured. We provide a full list of analytes, internal standards and abbreviations in Supplemental Materials Table S4.

We added each sample  $(10 \mu)$  of goldfish plasma for AA and BA or  $50 \mu$ l for all other metabolites) to a 96-well filter plate (Pall Corporation, Port Washington, NY, USA) that was fortified with an internal standard mix (Table S5). We then dried the plates were under liquid nitrogen, and we derivatized the AAs and BAs using Edman's Reagent<sup>35</sup>. After drying, we added  $250 \mu$ L of 5 mM ammonium acetate in methanol to each well, and the plate was shaken for 30 min. We eluted the samples into a Nunc 96-deep well plate (Thermo Scientific, Waltham, MA, USA) by centrifugation (100 g for 2 min at ambient temperature) and diluted with an equivalent volume of water (methanol for ACs, PCs, and SM) prior to analysis.

We measured the concentrations of metabolites using an Agilent 1100 high performance liquid chromatography (HPLC) system (Agilent, Palo Alto, California, USA) coupled to an API4000 triple quadrupole mass spectrometer (Applied Biosystems/Sciex, Concord, ON, Canada). AAs and BAs were analyzed as phenylthiocarbamyl derivatives.  $\Sigma$ Hexose, FAs and bile acids were analyzed separately by HPLC–MS/MS. All these analytes were quantified by isotope dilution/surrogate quantification using a 5–7 calibration curve generated from authentic native standards. ACs, SMs and PCs were measured using flow-injection MS/MS (FI-MS/MS). After deconvolution of overlapping isotopic peaks<sup>36</sup>, we quantified the lipid analytes relative to an internal standard. Mean method detection limits for each target metabolite are available in Table S6.

We processed and analyzed three blanks and three internal reference human serum samples (MP Biomedicals, Santa Ana, California, USA) with each batch of samples. We used the blanks to estimate background concentrations of metabolites during sample workup, and the reference samples to estimate analytical precision through sample workup. In addition, we ran a calibration sample every 20 samples to assess instrument stability, and we ran instrument methanol blank samples after high concentration calibration samples to assess sample carryover on the instrument. We previously validated the method at two different spiking levels (n = 5) in human plasma and then verified the method for goldfish plasma by analysing different sample amounts to assess appropriate sample size and to assess potential for interferences specific to goldfish plasma.

**Statistical and Bioinformatics Analyses.** For fish biometrics (Liver somatic index, LSI; Gonadal somatic index, GSI; and Condition Factor, K), and Vtg, we visually examined the data using box-whisker plots, and then tested to see if they met the assumptions of normality using Statistix 10. We verified agreement with the assumptions of normality and homogeneity of variance using the Shapiro-Wilk statistic, Levene test, O'Briens's test, and Brown and Forsythe test (one-way analysis of variance). When data did not conform to these assumptions of ANOVA, we adjusted the data using logarithmic transformations and when transformed data still did not meet those assumptions, we tested for significant difference using the non-parametric Kruskal-Wallis test.

We used the NCBI non-redundant database to match valid protein IDs to the closest human protein ortholog using the protein BLAST tool so that we could use the corresponding human gene symbol for functional analysis. In cases where there was more than one peptide or set of peptides matched to the same protein (this can happen when different peptides are matched to the same protein for different species in the database), we consolidated the data manually using Excel to calculate new mean intensities, number of peptides, and percent protein coverage; we selected the lowest FDR and highest SPI values to represent the quality of these consolidated protein IDs. We included single peptide IDs if their FDR was <1%.

We manually searched for and then matched metabolites to Human Metabolome Database (HMDB) numbers for functional analysis. We used Metaboanalyst 3.0 to calculate all fold change values and to perform Analysis of Variance (ANOVAs) with Fisher's LSD post-hoc test to determine differences in protein and metabolite data between sites. We retained the Metaboanalyst default settings for metabolite concentration data, while median normalization with pareto-scaling was selected for protein peak intensity data. We used the metabolite and protein data from male goldfish caged at the reference site (JH) as the reference for fold change calculations on the wild male goldfish data.

We used QIAGEN's Ingenuity<sup>®</sup> Pathway Analysis (IPA) software (QIAGEN Redwood City, www.qiagen.com/ ingenuity) to determine the biological functions for both metabolite and protein IDs together (core analysis). We uploaded pooled data for each location into the application, with corresponding human gene symbol or HMDB identifiers and fold change values based upon comparison to the reference site (JH). IPA mapped each identifier to its corresponding object in Ingenuity's Knowledge Base. IPA overlaid these molecules, called network eligible molecules, onto a global molecular network developed from information contained in Ingenuity's Knowledge Base, and then algorithmically generated functional networks based on their connectivity. Core analysis identified the biological functions and/or diseases that were most significant to the data set. IPA used the right-tailed Fisher's Exact Test to calculate a *p*-value determining the probability that each biological function assigned to that data set is due to chance alone. IPA also calculated the overlap p-value using the one-sided Fisher's Exact Test as a measure of the enrichment of the dataset (i.e. how much of the dataset overlaps with the known regulators in Ingenuity's Knowledge Base). Finally, the IPA software calculated an activation z-score for each biological function which takes into account the predicted direction of expression (based upon the Ingenuity Knowledge Base) versus the observed direction of expression within the dataset to infer whether the function is activated (z-score >+2) or inhibited (z-score <-2). **Data availability.** All data generated or analysed during this study are included in this published article and in Supplementary Information

#### References

- 1. Brown, D., Snow, D., Hunt, G. A. & Bartelt-Hunt, S. L. Persistence of Pharmaceuticals in Effluent-Dominated Surface Waters. 44, 299–304 (2015).
- Metcalfe, C. D. Pharmaceutical contaminants of emerging concern in the environment. *Environ. Toxicol. Chem.* 32, 1683–1684 (2013).
- Rivera-Utrilla, J., Sanchez-Polo, M., Angeles Ferro-Garcia, M., Prados-Joya, G. & Ocampo-Perez, R. Pharmaceuticals as emerging contaminants and their removal from water. A review. 93, 1268–1287 (2013).
- 4. Pereira, A. M. P. T., Silva, L. J. G., Meisel, L. M., Lino, C. M. & Pena, A. Environmental impact of pharmaceuticals from Portuguese wastewaters: geographical and seasonal occurrence, removal and risk assessment. **136**, 108–119 (2015).
- Mehinto, A. C., Hill, E. M. & Tyler, C. R. Uptake and Biological Effects of Environmentally Relevant Concentrations of the Nonsteroidal Anti-inflammatory Pharmaceutical Diclofenac in Rainbow Trout (Oncorhynchus mykiss). 44, 2176–2182 (2010).
- 6. Stancova, V. et al. Effects of Mixture of Pharmaceuticals on Early Life Stages of Tench (Tinca tinca). BioMed Res. Int. (2014).
- 7. Xie, Z. *et al.* Behavioral and biochemical responses in freshwater fish Carassius auratus exposed to sertraline. *Chemosphere* **135**, 146–155 (2015).
- Saravanan, M., Devi, K. U., Malarvizhi, A. & Ramesh, M. Effects of Ibuprofen on hematological, biochemical and enzymological parameters of blood in an Indian major carp, Cirrhinus mrigala. *Environ. Toxicol. Pharmacol.* 34, 14–22 (2012).
- 9. Kidd, K. A. et al. Direct and indirect responses of a freshwater food web to a potent synthetic oestrogen. Philos. Trans. R. Soc. B-Biol. Sci. 369 (2014).
- de Assis, H. C. S. et al. Estrogen-like Effects in Male Goldfish Co-exposed to Fluoxetine and 17 Alpha-Ethinylestradiol. Eviron. Sci. Technol. 47, 5372–5382 (2013).
- 11. (ed International Joint Commission) (The Government of Canada and The Government of the United States of America, 2012).
- Royal Botanical Gardens, Wetland Restoration Backgrounder, http://www.rbg.ca/files/pdf/exploreandlearn/naturallands/ WetlandRestorationBackgrounder.pdf (2010).
- Mayer, T. et al. Dispersal of Contaminants from Municipal Discharges as Evidenced from Sedimentary Records in a Great Lakes Coastal Wetland, Cootes Paradise, Ontario. J. Great Lakes Res. 34, 544–558 (2008).
- McKenzie, D. J. et al. Complex physiological traits as biomarkers of the sub-lethal toxicological effects of pollutant exposure in fishes. Philos. Trans. R. Soc. B-Biol. Sci. 362, 2043–2059 (2007).
- Tooby, T. E., Lucey, J. & Stott, B. The tolerance of grass carp, ctenopharyngodon-idella val to aquatic herbicides. J. Fish Biol. 16, 591–597 (1980).
- Piironen, J. & Holopainen, I. J. A note on seasonality in anoxia tolerance of crucian carp (carassius-carassius (l)) in the laboratory. Ann. Zool. Fenn. 23, 335–338 (1986).
- Lougheed, V. L., Theysmeyer, T. S., Smith, T. & Chow-Fraser, P. Carp exclusion, food-web interactions, and the restoration of Cootes Paradise Marsh. J. Great Lakes Res. 30, 44–57 (2004).
- Kavanagh, R. J. et al. Endocrine disruption and altered gonadal development in white perch (Morone americana) from the lower Great Lakes region. Environ. Health Perspect. 112, 898–902 (2004).
- 19. Simmons, D. et al. Reduced anxiety is associated with the accumulation of six serotonin reuptake inhibitors in wastewater treatment effluent exposed, goldfish Carassius auratus. Sci. Rep. 7 (2017).
- 20. Muir, D. et al. Bioaccumulation of pharmaceuticals and personal care product chemicals in fish exposed to wastewater effluents in an urban wetland. Sci. Rep. 7 (2017).
- 21. Simmons, D. B. D. et al. Omics for aquatic ecotoxicology: Control of extraneous variability to enhance the analysis of environmental effects. Environ. Toxicol. Chem. 34, 1693–1704 (2015).
- 22. Wishart D. S. *et al.* DrugBank: a comprehensive resource for in silico drug discovery and exploration. 34. D668-672, https://www. drugbank.ca/drugs/DB01241 (2006).
- Lyssimachou, A., Thibaut, R., Gisbert, E. & Porte, C. Gemfibrozil modulates cytochrome P450 and peroxisome proliferationinducible enzymes in the liver of the yellow European eel (Anguilla anguilla). *Environ. Sci. Pollut. Res.* 21, 862–871 (2014).
- 24. Mehta, N., Ozick, L. A. & Gbadehan, E. Drug-Induced Hepatotoxicity. http://emedicine.medscape.com/article/169814-overview (2016).
- 25. Smith, E. M. et al. In vitro inhibition of cytochrome P450-mediated reactions by gemfibrozil, erythromycin, ciprofloxacin and fluoxetine in fish liver microsomes. Aquat. Toxicol. 109, 259–266 (2012).
- 26. Jaeschke, H. et al. Forum Mechanisms of hepatotoxicity. Toxicol. Sci. 65, 166-176 (2002).
- Devarbhavi, H. & Andrade, R. J. Drug-Induced Liver Injury Due to Antimicrobials, Central Nervous System Agents, and Nonsteroidal Anti-Inflammatory Drugs. Semin. Liver Dis. 34, 145–161 (2014).
- Higgins, L. G. & Hayes, J. D. Mechanisms of induction of cytosolic and microsomal glutathione transferase (GST) genes by xenobiotics and pro-inflammatory agents. *Drug Metab. Rev.* 43, 92–137 (2011).
- 29. Skolness, S. Y. et al. Effects of gemfibrozil on lipid metabolism, steroidogenesis, and reproduction in the fathead minnow (Pimephales promelas). Environ. Toxicol. Chem. 31, 2615–2624 (2012).
- Prindiville, J. S., Mennigen, J. A., Zamora, J. M., Moon, T. W. & Weber, J. M. The fibrate drug gemfibrozil disrupts lipoprotein metabolism in rainbow trout. *Toxicol. Appl. Pharmacol.* 251, 201–208 (2011).
- Nathan, L. R., Jerde, C. L., Budny, M. L. & Mahon, A. R. The use of environmental DNA in invasive species surveillance of the Great Lakes commercial bait trade. *Conserv. Biol.* 29, 430–439 (2015).
- 32. Simmons, D. B. D. et al. Proteomic Profiles of White Sucker (Catostomus commersonii) Sampled from within the Thunder Bay Area of Concern Reveal Up-Regulation of Proteins Associated with Tumor Formation and Exposure to Environmental Estrogens. Environ. Sci. Technol. 46, 1886–1894 (2012).
- Tkatcheva, V. et al. Lithium an emerging contaminant: Bioavailability, effects on protein expression, and homeostasis disruption in short-term exposure of rainbow trout. Aquat. Toxicol. 161, 85–93 (2015).
- Benskin, J. P. et al. Distinctive Metabolite Profiles in In-Migrating Sockeye Salmon Suggest Sex-Linked Endocrine Perturbation. Environ. Sci. Technol. 48, 11670–11678 (2014).
- 35. Edman, P. & Begg, G. A Protein Sequenator. Eur. J. Biochem. 1, 80 (1967).
- Liebisch, G., Lieser, B., Rathenberg, J., Drobnik, W. & Schmitz, G. High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* 1686, 108–117 (2004).

#### Acknowledgements

Funding for this study was provided in part by the Government of Canada's Great Lakes Action Plan. Funding for metabolomics analysis by Axys was provided by the Government of Canada's Build in Canada Program. We thank the Royal Botanical Gardens for permission to work in Cootes Paradise. We particularly thank Tys Theysmeyer,

Jennifer Bowman, and Andrea Court who assisted with the wild fish collection and the cage deployments. We thank Natural Resources Canada, Atlas of Canada, for permission to use map information for Cootes Paradise and Jordan Harbour under the Open Government Licence – Canada (Fig. 1).

#### **Author Contributions**

D.S. performed proteomic analyses, analyzed the data, and prepared the manuscript. J.S. and D.S. designed the study. B.C. and J.C. performed targeted metabolomic analysis. J.M. and E.M. conducted field work. S.C. conducted vitellogenin analysis. E.M., S.B., J.S., B.C., and J.M. helped with manuscript preparation and edits.

#### Additional Information

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-12473-6.

Competing Interests: The authors declare that they have no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017